Recent gene therapy approaches delivering CYP46A1 into the striatum of HD models have improved neuronal atrophy, reduced mHTT aggregates, and enhanced motor behavior, accompanied by boosted cholesterol metabolism—increased 24-HC production, elevated cholesterol precursor levels, and upregulated cholesterogenic enzyme expression [47,49,305,308]. Here, CYP46A1 is linked to Huntington disease.